Fig. 1. SIRT2 expression is decreased in the hippocampus of an animal model of depression and MDD patients. (A) Representative blots in hippocampus extracts (left). Quantification of the experiments showed decreased levels of ΔFosB and SIRT2 in the hippocampus of mice under CUS (n=3 per group) (right). (B) Representative blots of hippocampus extracts (left). Quantification showed decreased levels of ΔFosB and SIRT2 in the hippocampus of mice under CRS (n=3~4 per group). (C) ChIP assays. Binding of ΔFosB to the Sirt2 promoter was decreased in the hippocampus of mice under CUS (n=3 per group). (D) Sirt2 and β-actin mRNA levels measured by qPCR in hippocampi of mice under CUS (n=3 per group). (E) ChIP assays. Binding of ΔFosB to the Sirt2 promoter was decreased in the hippocampus of mice under CRS (n=3 per group). (F) Sirt2 and β-actin mRNA levels were quantified by qPCR in hippocampus of mice under CRS (n=3 per group). (G) Microarray analysis (dataset accession number GSE53987) of post-mortem MDD hippocampal samples confirmed the reduction in SIRTs. (H) SIRT2 was down-regulated in post-mortem hippocampal tissue from subjects with MDD. Using appropriate sample selection criteria, we performed gene expression analyses on 14 hippocampus samples; 4 from patients with MDD and 10 controls. Data are mean±s.e.m. Unpaired t tests; *p<0.05, **p<0.01.
© Exp Neurobiol
